KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Non-cash Items: 2011-2024

Historic Non-cash Items for Sarepta Therapeutics (SRPT) over the last 3 years, with Dec 2024 value amounting to $425.0 million.

  • Sarepta Therapeutics' Non-cash Items rose 7041.17% to $425.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $425.0 million, marking a year-over-year increase of 7041.17%. This contributed to the annual value of $6.3 million for FY2024, which is 5.31% up from last year.
  • Per Sarepta Therapeutics' latest filing, its Non-cash Items stood at $425.0 million for Q4 2024, which was up 7,041.17% from $6.0 million recorded in Q4 2023.
  • In the past 5 years, Sarepta Therapeutics' Non-cash Items registered a high of $557.9 million during Q4 2022, and its lowest value of $2.0 million during Q4 2020.
  • In the last 3 years, Sarepta Therapeutics' Non-cash Items had a median value of $425.0 million in 2024 and averaged $329.6 million.
  • Its Non-cash Items has fluctuated over the past 5 years, first soared by 12,198.98% in 2021, then slumped by 98.93% in 2023.
  • Sarepta Therapeutics' Non-cash Items (Quarterly) stood at $2.0 million in 2020, then skyrocketed by 12,198.98% to $248.5 million in 2021, then soared by 124.54% to $557.9 million in 2022, then tumbled by 98.93% to $6.0 million in 2023, then skyrocketed by 7,041.17% to $425.0 million in 2024.
  • Its Non-cash Items was $425.0 million in Q4 2024, compared to $6.0 million in Q4 2023 and $557.9 million in Q4 2022.